ALK-Abello B (0OIR)
London Exchange · UK · prices in DKK · close of 23 Oct 2026
Key indicators
| Last close | DKK 149.45 |
|---|---|
| 52-week range | 149.45 – 271.60 |
| Return, 1 month / 3 months | +0.0% / +0.0% |
| Return, 1 year / 3 years | +1.1% / +1.1% |
| Trend | Below its 200-day average |
| RSI (14) | 45 |
| Volatility (1 year) | 317.2% |
| Worst drawdown (1 year) | -44.4% |
| Average daily value traded | 4.34M DKK |
| Dividend yield | 1.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
ALK-Abello is a Danish pharmaceutical company that focuses on allergy treatment. It develops and makes allergy immunotherapy products, including tablets and injections that help people with allergic conditions such as hay fever, allergic asthma and house dust mite allergy. The company serves patients and healthcare professionals, and its products are used in markets around the world. Its headquarters are in Denmark, and its work centres on diagnosing and treating allergic disease through immunotherapy.
The shares are listed on the London Exchange in UK under the code 0OIR, and the price on this page is in Danish kroner (DKK). Our dividend records, which start in 2019, show payments in one calendar year. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
ALK-Abello B (0OIR) trades on the London Exchange in UK. It last closed at DKK 149.45 on 23 October 2026.
Its price-based Market X-Ray is 34 out of 100 (a weak price profile), ranking 2,888 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 1.1% and over the last three months it rose 0.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 31 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -12.6% | ||
| From 52-week high | -44.4% | ||
| Momentum | 50 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 0.0% | ||
| 6-month return | 0.0% | ||
| 12-month return, skipping the last month | 1.1% | ||
| Stability (higher is calmer) | 13 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 317.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -44.4% | ||
| Liquidity | 67 · Fair | Moderate trading activity. | |
| Average daily value traded | 4.34M DKK | ||
| Zero-volume days | 1.7% | ||
| Income | 9 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.1% | ||
| Years with dividends | 1 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | +0.0% |
| 3 months | +0.0% |
| 6 months | +0.0% |
| 1 year | +1.1% |
| 3 years | +1.1% |
| 5 years | +4.3% |
Signals
| 50-day / 200-day average | 173.80 / 171.09 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 55.41 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 17 Mar 2026 | DKK 1.6000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.